Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.

Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, Mankin H, Duan Z.

Anticancer Res. 2011 Apr;31(4):1115-23.

PMID:
21508354
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.

Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, Mankin H, Duan Z.

Cancer Chemother Pharmacol. 2011 Feb;67(2):439-46. doi: 10.1007/s00280-010-1344-7. Epub 2010 May 12.

PMID:
20461381
[PubMed - indexed for MEDLINE]
3.

Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.

Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, Lev DC.

Clin Cancer Res. 2009 May 15;15(10):3472-83. doi: 10.1158/1078-0432.CCR-08-2714. Epub 2009 May 5.

PMID:
19417021
[PubMed - indexed for MEDLINE]
Free Article
4.
5.

Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.

Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP.

J Natl Cancer Inst. 2007 Jul 18;99(14):1107-19. Epub 2007 Jul 10.

PMID:
17623797
[PubMed - indexed for MEDLINE]
Free Article
6.

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.

Tula-Sanchez AA, Havas AP, Alonge PJ, Klein ME, Doctor SR, Pinkston W, Glinsmann-Gibson BJ, Rimsza LM, Smith CL.

Cancer Biol Ther. 2013 Oct 1;14(10):949-61. doi: 10.4161/cbt.25941. Epub 2013 Aug 2.

PMID:
23982416
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein.

Kang MR, Lee K, Kang JS, Lee CW, Lee KH, Kim JH, Yang JW, Kim BG, Han G, Kang JS, Park SK, Kim HM.

Oncol Rep. 2010 Mar;23(3):801-9.

PMID:
20127023
[PubMed - indexed for MEDLINE]
8.

Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.

Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D.

Gynecol Oncol. 2014 Jun;133(3):599-606. doi: 10.1016/j.ygyno.2014.03.007. Epub 2014 Mar 11.

PMID:
24631446
[PubMed - indexed for MEDLINE]
9.

[Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].

Zhang L, Ma YP, Jia G.

Zhonghua Xue Ye Xue Za Zhi. 2012 Nov;33(11):926-31. Chinese.

PMID:
23363750
[PubMed - indexed for MEDLINE]
Free Article
10.

Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells.

Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW.

Int J Cancer. 2002 May 10;99(2):292-8.

PMID:
11979447
[PubMed - indexed for MEDLINE]
11.

Modulation of radiation response by histone deacetylase inhibition.

Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):223-9.

PMID:
15850925
[PubMed - indexed for MEDLINE]
12.

RuvBL2 is involved in histone deacetylase inhibitor PCI-24781-induced cell death in SK-N-DZ neuroblastoma cells.

Zhan Q, Tsai S, Lu Y, Wang C, Kwan Y, Ngai S.

PLoS One. 2013 Aug 16;8(8):e71663. doi: 10.1371/journal.pone.0071663. eCollection 2013.

PMID:
23977108
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.

Ninios YP, Sekeri-Pataryas KE, Sourlingas TG.

Leuk Res. 2010 Jun;34(6):786-92. doi: 10.1016/j.leukres.2009.09.004. Epub 2009 Sep 25.

PMID:
19782399
[PubMed - indexed for MEDLINE]
14.

The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.

Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1131-40. doi: 10.1007/s00280-010-1455-1. Epub 2010 Sep 14.

PMID:
20838997
[PubMed - indexed for MEDLINE]
16.

CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.

Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA.

Mol Cancer Ther. 2006 May;5(5):1309-17.

PMID:
16731764
[PubMed - indexed for MEDLINE]
Free Article
17.

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.

Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7. Epub 2007 Nov 27.

PMID:
18042714
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines.

Jasek E, Gajda M, Lis GJ, JasiƄska M, Litwin JA.

Anticancer Res. 2014 Apr;34(4):1849-56.

PMID:
24692719
[PubMed - indexed for MEDLINE]
19.

Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.

Chikamatsu K, Ishii H, Murata T, Sakakura K, Shino M, Toyoda M, Takahashi K, Masuyama K.

Cancer Sci. 2013 Nov;104(11):1468-75. doi: 10.1111/cas.12271. Epub 2013 Oct 1.

PMID:
23992541
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk